Unlock instant, AI-driven research and patent intelligence for your innovation.

Effective doses of adenovirus-based biological delivery and expression system for treatment of human osteoarthritis and compositions comprising same

A technology of biological delivery and expression system, applied in the direction of drug combination, biochemical equipment and methods, virus, etc.

Pending Publication Date: 2022-06-10
PACIRA PHARMA INC
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the mechanisms of action of these various treatments are not fully understood
Consequently, these currently used therapies have shown only limited efficacy in the treatment of OA, and the success of treatment often depends on the severity of the case
In addition, these drugs must be administered frequently, sometimes even in combination with each other
Such frequent injections of drugs into joints are laborious, risk infection, are stressful to the subject and are expensive
Additionally, surgery for the treatment of OA often shows low efficacy and is usually performed only in severely advanced subjects
Thus, there is a clear and unmet medical need for more effective, sustained and cost-effective OA treatments

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Effective doses of adenovirus-based biological delivery and expression system for treatment of human osteoarthritis and compositions comprising same
  • Effective doses of adenovirus-based biological delivery and expression system for treatment of human osteoarthritis and compositions comprising same
  • Effective doses of adenovirus-based biological delivery and expression system for treatment of human osteoarthritis and compositions comprising same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0262] Purpose of the study: This article describes studies to determine year-long long-term gene expression in the joints of mice injected intra-articularly with the expression of firefly luciferase (luc) under the control of the CMV promoter. Invented helper-dependent adenoviral vector (HDAd) and first-generation adenoviral (Ad) vectors for comparison.

[0263] Method: intra-articular injection of 10 8 Luciferase-expressing helper-dependent adenoviral vector (HDAd-luc) or the corresponding first-generation adenoviral vector (Ad-luc) expressing viral particles (VP). Injection into two knee joints of four mice per group. Three days later, mice were imaged using an MS 200 series imaging system (Caliper Life Sciences, Hopkinton, MA). Repeated bioluminescent imaging was performed following mouse luciferase expression and quantified using Living Image 2.5 software (Caliper Life Sciences).

[0264] Results: Strong bioluminescence signals were detected in joints injected with HDA...

Embodiment 2

[0267] This article describes studies used to evaluate HDAd transduction in the joints of mice in detail, in which mice were injected intra-articularly with 10 8 or 10 9 VP HDAd expressing LacZ. in use 10 9 Strong expression of LacZ was seen in both synovium and chondrocytes of VP LacZ-expressing HDAd-infected joints ( Figure 5B ), while at 10 8 No staining was observed in chondrocytes in VP-infected joints ( Figure 5A ). The livers of these animals were analyzed to assess whether the virus escaped from the joints or spilled out during injection. Most importantly, detectable carrier concentrations above background could not be measured by quantitative PCR (data not shown). Thus, the vector is specifically localized in the joints and remains there, which is of great benefit in the treatment or prevention of osteoarthritic conditions, since it shows minimal side effects.

[0268] Example 4: HDAd-11-1Ra infected cells secrete IL-1Ra. injection.

[0269] Purpose of the ...

Embodiment 3

[0272] Conclusions: The results disclosed herein demonstrate that cells infected with HDAd-mll-IRa can produce high levels of II-IRa. It has also been shown that IL-1Ra is efficiently secreted from these cells and that inflammatory conditions activate the NF-KB5-ELAM promoter, resulting in increased IL-1Ra levels.

[0273]Acute injury of the anterior cruciate ligament (ACL) is a common cause of post-traumatic OA in humans, and ACL transection (ACLT) in rats and mice is an established animal model of traumatic injury-induced OA. FX201, a helper-dependent adenovirus (HDAd)-based intra-articular (IA) gene therapy candidate designed to induce interleukin (IL)-1 receptors in the presence of inflammation, is being developed as a potential therapeutic agent for OA. production of an antagonist (IL-1Ra). This article describes studies demonstrating that treatment with FX201 or its equivalent HDAd-mIL-IRa is effective in the prevention and treatment of OA.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The present disclosure relates to pharmaceutical compositions and methods of using pharmaceutical compositions comprising an effective dose of an adenovirus-based biological delivery and expression system, the present invention relates to an adenovirus-based biological delivery and expression system for treating or preventing osteoarthritis in human or mammalian joints by long-term inducible gene expression of human or mammalian interleukin-1 receptor antagonist (IL-1Ra) in synovial cells, the present invention relates to an adenovirus-based biological delivery and expression system comprising a helper-dependent adenovirus vector, the helper-dependent adenoviral vector contains a nucleic acid sequence encoding a human or mammalian interleukin-1 receptor antagonist (IL-1Ra), left and right inverted terminal repeat sequences (L ITR and R ITR), an adenoviral packaging signal and a non-viral non-coding filler nucleic acid sequence, wherein the expression of the human or mammalian interleukin-1 receptor antagonist (IL-1Ra) gene in synovial cells is modulated by an inflammation-sensitive promoter.

Description

Cross References to Related Applications [0001] This application claims the benefit of U.S. Provisional Application No. 62 / 966,632, filed January 28, 2020, and U.S. Provisional Application No. 62 / 902,041, filed September 18, 2019, the contents of which are hereby incorporated by reference in their entirety . Incorporated by reference into the sequence listing [0002] This application contains a Sequence Listing which has been submitted via EFS-Web in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on September 16, 2020, is named "FLEX-011_001WO_Sequence Listing.txt" and is 117 kilobytes in size. Background technique [0003] Osteoarthritis (OA) is a degenerative joint disease that occurs in human or mammalian joints and constitutes a serious economic and medical problem (Matthews, G.L. and Hunter, D.J. (2011). Emerging drugs for osteoarthritis. Expert Opin. Emerging Drugs 1-13.; Brooks PM. Impact of osteoarthritis on indiv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00C07K14/54C12N15/86A61P19/02
CPCA61P19/02C12N15/86C12N2710/10343C07K14/545C07K14/7155A61K48/005A61K9/0019A61K38/00A61K48/00C12N2750/14122C12N2750/14142C12N2750/14171
Inventor S·凯利R·森特M·查比科夫斯基E·W·马丁N·博迪克W·洪K·汪M·道格拉斯J·D·杰克逊
Owner PACIRA PHARMA INC